Arterial hypertension Circulatory System
Conditions
Interventions
All participants undergo a baseline assessment as follows:
1. Neuropsychological assessment (MoCA, verbal fluency test, TMT (parts A and B), 10-words list learning task, Stroop Color a
Sponsors
Sechenov University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Hypertension group: 1. Age 40-59 years 2. Office SBP – 140–179 mmHg and/or DBP – 90–109 mmHg 3. Presence of at least one hypertension-mediated organ damage (heart – left ventricular hypertrophy assessed by echocardiogram, blood vessels – atherosclerotic plaques assessed by triplex scanning of the brachiocephalic arteries, kidneys – microalbuminuria and/or glomerular filtration rate according to CKD-EPI between 30-60 ml/min/1.73 m²) 4. Lack of antihypertensive treatment Control group 1. Healthy men and women 2. Age 40-59 years 3. Absence of hypertension
Exclusion criteria
Exclusion criteria: 1. Body mass index = 40 kg/m² 2. Pregnancy, lactation 3. Clinically significant heart disease (myocardial infarction, 2nd and 3rd degree atrio-ventricular block without artificial pacemaker, sinoatrial block, sick sinus syndrome, hypertrophic cardiomyopathy, aortic and mitral stenosis, chronic heart failure, angina pectoris) 4. Clinically significant liver disease 5. Clinically significant kidney disease (GFR according to CKD-EPI <30 ml/min / 1.73 m², hemodialysis, anuria) 6. Clinically significant respiratory organ disease (including bronchial asthma and chronic obstructive pulmonary disease) 7. Clinically significant immunological disease 8. Clinically significant endocrine disease (including diabetes mellitus) 9. Secondary hypertension 10. Gout 11. Mental illness and disorders, dementia, drug and alcohol abuse 12. Severe peripheral vascular diseases (including Raynaud's syndrome) 13. Metabolic acidosis 14. Refractory hypokalemia 15. Clinically significant neurological diseases (including stroke and transient ischemic attack) 16. Surgical operation in the previous 3 months (excluding dental or plastic surgery) 17. Use of any medication (including regular intake of antihypertensive treatment) that could have affected the results of the study for 12 weeks before enrollment, at the time of enrollment and until the end of the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| At baseline and follow-up 1. Blood pressure measured using sphygmomanometer 2. Cognitive function measured using MoCA, verbal fluency test, TMT (parts A and B), 10-words list learning task, Stroop Color and Word Test 3. Cerebral blood flow measured using fMRI | — |
Secondary
| Measure | Time frame |
|---|---|
| Fractional anisotropy measured using fMRI at baseline and follow-up | — |
Countries
Russian Federation
Outcome results
None listed